ANTWERP, Belgium – April 2, 2012 – Bruker Corporation today announced that it has acquired all of the shares of SkyScan N.V., a scientific instruments company located near Antwerp, Belgium. Financial details were not disclosed. For the remainder for 2012, the acquisition of SkyScan is expected to add approximately $13 million to Bruker’s revenue and to be accretive to EPS by about $0.01. SkyScan’s revenue is derived approximately 50% from materials science and 50% from life science and preclinical imaging applications.
Find out who’s doing what in microCT, or let the world know what you do!
There is now a dedicated microCT world community map page on the blog! Check it out to navigate through the microCT community. You’ll find scanner manufacturers, service providers, research labs, and more. Please, consider this as a living document that will take some time to be populated. If you are a professional who wants to be listed on the map, drop a comment on the dedicated page. Only companies / institutes / individuals who explicitly ask to be listed on the map will be included.
I hope you’ll find the map a useful tool and would be happy to receive any suggestion you may have.
Over the past years, the topic of quality assurance (QA) has been a steady companion and although I might not necessarily like QA on f, there’s no doubt that thinking of negatively influencing variables of a working process is strengthening the awareness of potential issues and therefore still earns a +1 on g. Developing and implementing standard operating procedures (SOP) is then the next step after the detailed risk assessment of a process and aims to standardize the findings of the expert, who is aware of all influencing variables and context-specific dependencies. And by fixing this approach into a written SOP, it can be ensured that the results obtained by following this procedure are consistent and don’t require the expert’s knowledge. Despite this rather short and simplified description of QA, it is probably common-sense that the benefit of eliminating (or at least consistently managing) critical issues of the process generally increases the quality of the results.
The theoretical basis of Computed Tomography (CT) finds its origins in 1917, when the Austrian mathematician Johan Radon (16 December 1887 – 25 May 1956) proved that an n-dimensional object can be reconstructed from its (n-1)-dimensional projections . However, only in the second half of the century the mathematical basis for the actual CT image reconstruction was presented in two papers by Allan M. Cormack (Feb. 23, 1924 – May 7, 1998) [2, 3] in 1964 and 1965, respectively.
WALTHAM, Mass.–(BUSINESS WIRE)– PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and the environment, today announced that the Company has completed its acquisition of Caliper Life Sciences, Inc. (NASDAQ: CALP), a Hopkinton, Massachusetts-based leader in imaging and detection solutions for life sciences research, diagnostics and environmental markets. In September, PerkinElmer announced its intent to acquire Caliper for $10.50 per share, for a total net purchase price of approximately $600 million in cash.
BV/TV, Tb.Th., Tb.Sp. and the other usual suspects: what do they really mean?
If you are asking yourself this question, you should definitely read this! Coming soon in the same series: Trabecular Thickness (Tb.Th) and Trabecular Spacing (Tb.Sp), Bone surface density (BS/TV), Structure Model Index (SMI), Connectivity Density (Conn. D), and others. The “Light version” series is intended to those who are just approaching the field, or to those who are looking for a simple way to explain these concepts to others. If you are a professional, please insert your comments to help us making this post more complete and interesting.
WALTHAM, Mass.–(BUSINESS WIRE)– PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and the environment, today announced that it has signed a definitive agreement to acquire Caliper Life Sciences, Inc. (NASDAQ: CALP), a Hopkinton, Massachusetts-based leader in imaging and detection solutions for life sciences research, diagnostics and environmental markets, for $10.50 per share, for a total net purchase price of approximately $600 million in cash.